Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
xH8efGxEGwTHpvp7
